Introduction: Clinical guidelines generally recommend endocrine therapy over
asymptomatic visceral metastases are present [1, 2] . Cytotoxic chemotherapy has proven efficacy but, due to its tolerability profile, should be reserved for patients with rapidly progressing disease and/or endocrine resistance [1, 2] . Recommended endocrine therapies include the selective estrogen receptor modulator tamoxifen; third-generation aromatase inhibitors (AIs) anastrozole, letrozole, and exemestane; and the selective estrogen receptor downregulator fulvestrant [3] . Limited data are available for assessing the use of these treatments in routine practice. We report real-world use of these therapies for the treatment of postmenopausal patients with HR-positive, HER2-negative advanced breast cancer in Europe and the United States.
METHODS

Study Design and Participants
The Global Oncology MonitorÓ (Ipsos Healthcare, London, UK)-a large physician-based syndicated patient record database-was used to identify treatments given to postmenopausal patients with (Fig. 1) . In the third-line setting, endocrine therapy-only regimens were given less commonly than chemotherapy-only regimens in both Europe and the United States.
There were no clear differences in patterns of use between endocrine-only and chemotherapy-only regimens in the second-line setting. Table 1 for sample sizes). Ó Ipsos, all rights reserved c In Europe, when assessed by category, first-line treatment patterns appeared similar between chemotherapy-only and endocrine therapy-only regimens in patients with late-recurrent disease (Fig. 2) Table 1 for sample sizes). Ó Ipsos, all rights reserved found European practice patterns to be generally consistent with guideline recommendations [7] . However, to our knowledge, there have been no published studies that have investigated the differences in practice patterns for advanced breast cancer between the United States and Europe.
Therefore, initial study could prompt more in-depth investigation.
It is possible that the apparent low utilization of endocrine therapy for advanced breast cancer, especially as second-and third-line therapies, may be because patients develop rapidly progressing disease after first-line treatment (possibly also with the presence of life-threatening visceral metastases), making them candidates for chemotherapy. Alternatively, physicians may have reasons to expect further lines of endocrine therapy to lack benefit due to the development of endocrine resistance [8] , or they may be willing to concede the increased toxicity with chemotherapy with an expectation of achieving more effective disease control [4] . This could be interpreted as a belief by some physicians that the risk-benefit profile of endocrine therapies in the second-and third-line settings are not superior to chemotherapy [4] . However, these speculations extend beyond the current study, and the relevant data regarding physicians' motivations for therapy choice were not collected. 
